A citation-based method for searching scientific literature

Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson, Gabriela Plesa, Fang Chen, Megan M Davis, Wei-Ting Hwang, Regina M Young, Jennifer L Brogdon, Randi Isaacs, Iulian Pruteanu-Malinici, Don L Siegel, Bruce L Levine, Carl H June, Michael C Milone. J Clin Invest 2019
Times Cited: 304



Ujjawal H Gandhi, Robert F Cornell, Arjun Lakshman, Zhubin J Gahvari, Elizabeth McGehee, Megan H Jagosky, Ridhi Gupta, William Varnado, Mark A Fiala, Saurabh Chhabra, Ehsan Malek, Joshua Mansour, Barry Paul, Alyssa Barnstead, Saranya Kodali, Amarendra Neppalli, Michaela Liedtke, Swapna Narayana, Kelly N Godby, Yubin Kang, Ankit Kansagra, Elvira Umyarova, Emma C Scott, Parameswaran Hari, Ravi Vij, Saad Z Usmani, Natalie S Callander, Shaji K Kumar, Luciano J Costa. Leukemia 2019
Times Cited: 182




List of shared articles



Times cited

Recommendations on the management of multiple myeloma in 2020.
Marie-Christiane Vekemans, Chantal Doyen, Jo Caers, Kalung Wu, Alain Kentos, Philippe Mineur, Lucienne Michaux, Michel Delforge, Nathalie Meuleman. Acta Clin Belg 2022
1




The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.
José-Ángel Hernández-Rivas, Rafael Ríos-Tamayo, Cristina Encinas, Rafael Alonso, Juan-José Lahuerta. Biomark Res 2022
0

Current state and next-generation CAR-T cells in multiple myeloma.
Salomon Manier, Tiziano Ingegnere, Guillaume Escure, Chloé Prodhomme, Morgane Nudel, Suman Mitra, Thierry Facon. Blood Rev 2022
1

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
Ruiting Guo, Wenyi Lu, Yi Zhang, Xinping Cao, Xin Jin, Mingfeng Zhao. Front Immunol 2022
0


CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.
Juan Du, Runhong Wei, Songfu Jiang, Hua Jiang, Lu Li, Wanting Qiang, Haiyan He, Lin Shi, Qiuling Ma, Kang Yu,[...]. Am J Hematol 2022
0

BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.
Edmund Watson, Faouzi Djebbari, Alexandros Rampotas, Karthik Ramasamy. Expert Rev Hematol 2022
0

An update on novel multiple myeloma targets.
Massimo Offidani, Laura Corvatta, Sonia Morè, Maria Valentina Manieri, Attilio Olivieri. Expert Rev Hematol 2022
0

Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead.
Andrew J Cowan, Sherilyn A Tuazon, Andrew J Portuguese, Damian J Green. Cancer J 2021
2

A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.
Marc Braunstein, Jonathan Weltz, Faith Davies. Expert Rev Hematol 2021
3

A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Chunrui Li, Wenyue Cao, Yimei Que, Qiuxiang Wang, Yi Xiao, Chaojiang Gu, Di Wang, Jue Wang, Lijun Jiang, Hao Xu,[...]. Clin Transl Med 2021
9